Zoeken
Inloggen

TRAIN-3

  • Follow up

BOOG 2018-01

General Information

BOOG number

BOOG 2018-01

Nickname

TRAIN-3

Status

  • Follow up
Date: 18/05/2021

Inclusion closed

18/05/2021

Full title

Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer: the TRAIN-3 study

Indication

  • Neoadjuvant

Subindication

HER2+, any HR

Description

De-escalation of neoadjuvant chemotherapy

Target sample size

462

Actual accrual

472
Date: 18/05/2021

Estimated study completion date

01/10/2032

Contact

Sponsor

BOOG Study Center

Principal Investigator(s)

Prof. dr. G.S. Sonke MD PhD (The Netherlands Cancer Institute)

Study manager

Dr. A.E. van Leeuwen-Stok (BOOG Study Center)

Study coordinator

F. Louis, MD E: TRAIN3@nki.nl

Central datamanagement and randomization

Registration: Authorized persons at the site, through ALEA
Central contact Data Center: K. Pengel
NKI-AVL Data Center Phone +31 20 512 2618 E-mail k.pengel@nki.nl

Monitoring

NKI-AVL Data Center
Phone +31 20 512 2655
E-mail e.v.schaffelaar@nki.nl

Local datamanagement

Centrum zelf of IKNL
E-mail: trialbureau@iknl.nl
Phone +31 88 234 6500

Funding

Roche

Other

Contracts & finances: BOOG Study Center (info@boogstudycenter.nl)

Radiology: R. Mann, MD PhD: Ritse.Mann@radboudumc.nl

 

Klik hier voor een artikel van Medische Oncologie over de TRAIN-3-studie toegelicht door Joan Heijns, juni 2024

Design

Participating sites

  • Amphia Ziekenhuis
  • Amstelland Ziekenhuis
  • Bernhoven Ziekenhuis
  • Canisius Wilhelmina Ziekenhuis
  • Catharina Ziekenhuis
  • Deventer Ziekenhuis
  • Diakonessenhuis
  • Elisabeth-Tweesteden Ziekenhuis
  • Franciscus Gasthuis & Vlietland
  • Gelre Ziekenhuis
  • Haaglanden MC
  • Haga Ziekenhuis
  • Ikazia Ziekenhuis
  • Isala
  • Jeroen Bosch Ziekenhuis
  • Laurentius Ziekenhuis
  • Maasstad Ziekenhuis
  • Maastricht UMC+
  • Martini Ziekenhuis
  • Maxima MC
  • Medisch Centrum Leeuwarden
  • Meander MC
  • Nij Smellinghe
  • NKI-AVL
  • Noordwest Ziekenhuisgroep
  • OLVG
  • Reinier de Graaf
  • Rijnstate Ziekenhuis
  • Rivas Beatrix Ziekenhuis
  • Rivierenland Ziekenhuis
  • Rode Kruis Ziekenhuis
  • Spaarne Gasthuis
  • St. Anna Ziekenhuis
  • St. Antonius Ziekenhuis
  • Streekziekenhuis Koningin Beatrix
  • Tjongerschans Ziekenhuis
  • UMC Utrecht
  • Van Weel-Bethesda Ziekenhuis
  • Viecuri MC
  • Ziekenhuis St. Jansdal
  • Zaans Medisch Centrum
  • Ziekenhuisgroep Twente
  • ZorgSaam Ziekenhuis

Objectives

Primary efficacy objective

To evaluate efficacy of image-guided de-escalating chemotherapy in the presence of dual HER2-blockade with Herceptin® and pertuzumab in HER2-positive breast cancer, as measured by three-year event-free survival.

 

Secondary efficacy objectives

  • To evaluate 3-year overall survival
  • To evaluate pCR rate in breast and axilla
  • To evaluate 5-year, and 10-year overall and event-free survival rate
  • To evaluate the association between pCR and long-term outcome
  • To evaluate the association between radiologic complete response (rCR) and pCR
  • To evaluate the association between on‐treatment VACBs and pCR
  • To compare short-term and long-term efficacy by number of chemotherapy cycles received
  • To compare non-radical resection percentages between rCR and no rCR

 

Patient-reported outcome objective

To compare health‐related quality of life after receiving 3, 6 or 9 cycles of chemotherapy using the EORTC QLQ‐30 and QLQ‐BR45 questionnaires

 

Safety objectives

  • Incidence and severity of adverse events grade ≥3 (CTCAE v5.0)
  • Incidence and severity of cardiotoxicity and neuropathy grade ≥2
  • Incidence of symptomatic LVSD (heart failure), and incidence of asymptomatic decrease in LVEF, defined as an asymptomatic decline in LVEF requiring treatment or leading to discontinuation of pertuzumab and Herceptin®, or a decrease ≥10 percentage points from baseline to a LVEF <50%
  • Grade ≥3 laboratory test abnormalities

 

Exploratory objectives

  • To explore mechanisms of resistance to treatment based on immunohistochemistry and whole exome sequencing plus proteomics of pre-treatment and on-treatment biopsies, comparison of pre-treatment biopsies with residual tumor after treatment, sequential cfDNA and tumor-educated platelets.
  • To evaluate the effect of in vivo biotransformation of trastuzumab and pertuzumab on the treatment response

Endpoints

Primary efficacy outcome measure:

Event-free survival (EFS), defined as the interval from registration to the earliest occurrence of disease progression resulting in inoperability, invasive loco regional recurrence, distant metastases, or death from any cause, whichever comes first

 

Secondary efficacy outcome measures:

  • Overall survival (OS), defined as the time from registration to death from any cause
  • Pathologic complete response in breast and axilla, defined as the absence of invasive tumor cells, irrespective of the presence of in-situ lesions(ypT0/is,ypN0)
  • Radiologic complete response defined as the absence of pathologic enhancement on MRI and normalization of possible lymph node involvement at ultrasound and FNA examination
  • Number of neoadjuvant chemotherapy cycles administered
  • Number of radical and non-radical resections

 

Patient‐reported‐outcome measure:

Health‐related quality of life scored using the EORTC QLQ‐30 and BR‐45 questionnaires

 

Safety outcome measures:

  • Incidence and severity of adverse events grade ≥3 (CTCAE v5.0) until 30 days after last adjuvant treatment administration
  • Incidence and severity of cardiotoxicity and neuropathy grade ≥2
  • Incidence of symptomatic LVSD (heart failure), and incidence of asymptomatic decrease in LVEF, defined as an asymptomatic decline in LVEF requiring treatment or leading to discontinuation of pertuzumab and Herceptin, or a decrease ≥10 percentage points from baseline to a LVEF <50%
  • Grade ≥3 laboratory test abnormalities

 

Exploratory outcome measures:

  • PCR rate, 3-year EFS and OS stratified by the identified potential biomarkers
  • PCR rate, 3-year EFS and OS stratified by degree of biotransformation of trastuzumab and pertuzumab

Eligibility Criteria

Eligible patients must meet all of the following criteria:

  • Signed written informed consent o Histologically confirmed infiltrating breast cancer
  • Stage II or III disease according to TNM-staging (8th edition, AJCC).
  • Overexpression and/or amplification of HER2 in an invasive component of the core biopsy, according to ASCO/CAP 2013 guideline (locally assessed)
  • Known estrogen- and progesteron-receptor expression of the invasive tumor
  • Age ≥18 o WHO performance status ≤1
  • Visible breast tumor on contrast enhanced MRI and/or the presence of malignant lymph node(s)
  • Adequate bone marrow function, hepatic function, renal function
  • LVEF ≥50% measured by echocardiography, MUGA, or MRI
  • Women of childbearing potential and men must agree to remain abstinent (refrain from heterosexual intercourse) or use adequate contraceptive methods (failure rate of <1% per year,) during treatment and for at least seven months after the last dose of pertuzumab/Herceptin®.
  • Women who are not postmenopausal (≥12 months of non−therapy-induced amenorrhea) or surgically sterile must have a negative β-HCG serum or urine pregnancy test result.

 

Exclusion criteria:

A subject who meets any of the following criteria will be excluded from participation in this study:

  • Concurrent breast feeding o Evidence of distant metastases on FDG-PET
  • Concurrent contralateral or ipsilateral second primary infiltrating breast cancer
  • Concurrent anti-cancer treatment or another investigational drug
  • Contra-indication for neoadjuvant chemotherapy
  • Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Other invasive malignancy unless treated without chemotherapy more than five years ago and without evidence of recurrence. Patients with prior adequately treated basal cell or squamous cell skin cancer are also eligible.
  • Peripheral neuropathy ≥grade 2 CTCAE v5.0

Regulatory Information

CCMO approval

Yes
Date: 08/01/2019
Nr: NL66887.038.18

EC approval

Yes
Date: 07/02/2019
Nr:M18TRD

EC

Nederlands Kanker Instituut
Amendments:
Yes
Date Last Amendment: 19/05/2020

EudraCT number

2018-003275-35

Trial Register

NCT03820063

Downloads

Inloggen